Japanese CLL Patients' response to Venetoclax±Rituximab under the microscope
NCT ID NCT06362044
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in Japan looked at 89 adults with relapsed chronic lymphocytic leukemia (CLL) who took Venetoclax (with or without Rituximab) for 24 months. The main goal was to see how many had undetectable minimal residual disease (uMRD), a sign of deep response. Researchers collected data from routine clinic visits to understand real-world outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (oral tablet) with or without Rituximab (intravenous infusion)
What this could lead to
If successful, this study could help doctors understand how well Venetoclax±Rituximab works in Japanese patients with relapsed CLL, potentially guiding better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. The small size (89 patients) and focus on Japan may limit how widely findings apply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East /ID# 265970
Kashiwa-shi, Chiba, 277-8577, Japan